Clinical Trial Update: A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of sapanisertib in relapsed/refractory squamous non-small cell lung cancer (including NFE2L2-mutant and wild-type) has been terminated with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Squamous Cell Carcinoma of the Lung

Drugs mentioned

• Sapanisertib (sapanisertib)

Snippet

Sponsor: Faeth Therapeutics | Conditions: Non-Small Cell Lung Cancer, Squamous Non-small-cell Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2025-04-24